Skip to main content
Sister Publication Links
  • ESG: THE IMPLEMENTATION IMPERATIVE
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Digital Health
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Unwell in America
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Technology
May 13, 2017 01:00 AM

Sanofi vows to limit price hikes—but will it make much difference?

Alex Kacik
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    Drugmaker Sanofi's pledge last week to hold price hikes to the rate of healthcare inflation did little to allay concerns about the soaring costs of prescription medications.

    After a rash of public outcry about drug prices, several pharmaceutical companies have vowed to curtail increases that have squeezed the bottom lines of providers, payers and consumers alike. Sanofi's promise to link increases to the rise in the National Health Expenditure Data Accounts as tracked by the CMS—estimated to be 5.6% annually from 2016 to 2025—is a firmer commitment than has been made by other companies.

    Nonetheless, experts worry that prices will continue to be a drag on the entire healthcare system.

    "Drug price increases still far outpace medical inflation," said Dr. Scott Knoer, chief pharmacy officer of Cleveland Clinic. "The current model is unsustainable. We just can't have (drug price) inflation in double digits like we have had and provide healthcare medications to patients. It's a budget-buster."

    A better benchmark would be capping price increases at the Consumer Price Index, which has averaged around 1.4% since the Great Recession, experts said.

    Drug companies have been pressured to change their pricing policies after high-profile disputes like the one involving EpiPen. The emergency allergy drug's price grew 500% from 2007 to 2016.

    THE TAKEAWAY

    Sanofi's commitment to limit prices to the rise in the National Health Expenditure Data Accounts—estimated to be 5.6% annually from 2016 to 2025—is not enough, healthcare experts said.

    Big Pharma lobbyists claim that medical treatment is expensive and high prices are needed to fund research and development. Yet, research shows profits often significantly outpace R&D costs. Pharmaceutical companies contend that other players in the supply chain, such as pharmacy benefit managers, absorb much of the price increases.

    Dr. Roy Guharoy—Ascension Health's vice president of clinical integration and chief pharmacy officer for the Resource Group, an Ascension group purchasing organization—agreed that price hikes should be limited to the CPI. "High drug prices are a huge challenge to deliver care to patients in need," he said. "Sanofi's commitment is good, but we're still far from where we need to be."

    Systems, including Ascension, have had to shift treatment strategies to avoid overuse of high-cost drugs—some of which have no viable alternatives.

    National healthcare spending grew 5.8% to $3.2 trillion in 2015, in part due to a 9% increase in prescription spending to $324.6 billion.

    Branded drugs with no generic alternatives, or single-source drugs, are the main culprit, according to a recent Blue Cross and Blue Shield Association study. They are rising at an average annual rate of 25%, a total of 285% since 2010. These patent-protected drugs now make up 63% of total drug spending, up from 29% of total spending in 2010, despite the fact that they make up less than 10% of total prescriptions filled.

    In a column on the company's website, Sanofi CEO Olivier Brandicourt said that its average list price increases were 4%. The company will explain hikes if they outpace medical inflation and will disclose its aggregate gross and net price increases.

    Many branded drugs have increased at a much faster clip, including Sanofi's insulin drug Lantus, which increased 13% annually from 2010 to 2016.

    Botox maker Allergan said last fall that it would stick to single-digit price increases. Novo Nordisk, AbbVie, GlaxoSmithKline and Takeda Pharmaceuticals followed suit. Eli Lilly and Co. said it would lower prices for most of its insulins by up to 40%.

    "Competition is the answer to a lot of these huge price spikes," said William Woodward, senior director of sourcing operations for pharmacy at the GPO Vizient. "New drugs are priced at whatever the market will bear—it has little or no relation to costs for production or research and development."

    There are several bills moving through Congress that aim to reduce drug costs. Two bills, with the shorthand names CREATES Act and FAST Generics Act, target alleged anticompetitive behavior that stifles generic drug development. That alleged behavior includes preventing generic developers from accessing samples of branded products to demonstrate that a generic is equivalent and participating in blocking access to safety protocols needed to gain federal approval. It's estimated the bipartisan FAST Generics Act would reduce drug costs by $5.4 billion a year .

    Experts also supported reducing or even eliminating direct-to-consumer and direct-to-physician marketing. The pharmaceutical industry spent more than $24 billion to market directly to physicians in 2012 compared with $3 billion that year to consumers, according to a study published that year by Pew Charitable Trusts.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    IBM Quantum System One at Cleveland Clinic_4_0.jpg
    Cleveland Clinic, IBM unveil quantum computer
    Dr. Alice Zheng
    Women's digital health sector poised for growth, venture capitalist predicts
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Health IT Strategist (HITS) Newsletter: Sign up for the latest IT and medical technology news delivered 3 days a week (M, W, F).
     
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Digital Health
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Unwell in America
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing